Component

Dasatinib

Dasatinib

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.

    Apigenin → Dasatinib Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_condition
    Dasatinib alone Apigenin pretreatment plus dasatinib · Apigenin Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_condition
    Dasatinib alone oral partner drug · Dasatinib Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "Apigenin pretreatment plus dasatinib", "comparator": "Dasatinib alone", "endpoint": "Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.", "effect_direction": "increase", "combination": "joint", "conditions": [{"entity_slug": "apigenin", "state": "Apigenin pretreatment plus dasatinib"}, {"entity_slug": "dasatinib", "state": "oral partner drug"}]} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.
    primary_references
    Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602
    source_locator
    Reviewed reference api-rat-dasatinib; The abstract and Results describe pretreatment; regimen wording is imperfect in one Methods sentence. Rat exposure does not determine the human interaction magnitude.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 872–878

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7. · Recorded from source · Recorded from source

    ### api-rat-dasatinib Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats. The abstract and Results describe pretreatment; regimen wording is imperfect in one Methods sentence. Rat exposure does not determine the human interaction magnitude. Model and exposure: n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.

    Apigenin → Rat breast cancer resistance protein / Abcg2 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Apigenin pretreatment in the drug experiment", "comparator": "Drug-only controls", "endpoint": "Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Seven-day oral apigenin regimen with subsequent dasatinib exposure.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.
    primary_references
    Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602
    source_locator
    Reviewed reference api-rat-bcrp; Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 896–902

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Seven-day oral apigenin regimen with subsequent dasatinib exposure. · Recorded from source · Recorded from source

    ### api-rat-bcrp Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study. Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement. Model and exposure: Seven-day oral apigenin regimen with subsequent dasatinib exposure. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  2. Apigenin decreased measured hepatic/intestinal Rat cytochrome P450 3A2 / Cyp3a2 expression in the rat dasatinib study.

    Apigenin → Rat cytochrome P450 3A2 / Cyp3a2 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Apigenin pretreatment in the drug experiment", "comparator": "Drug-only controls", "endpoint": "Apigenin decreased measured hepatic/intestinal Rat cytochrome P450 3A2 / Cyp3a2 expression in the rat dasatinib study.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Seven-day oral apigenin regimen with subsequent dasatinib exposure.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin decreased measured hepatic/intestinal Rat cytochrome P450 3A2 / Cyp3a2 expression in the rat dasatinib study.
    primary_references
    Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602
    source_locator
    Reviewed reference api-rat-cyp3a2; Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 880–886

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Seven-day oral apigenin regimen with subsequent dasatinib exposure. · Recorded from source · Recorded from source

    ### api-rat-cyp3a2 Apigenin decreased measured hepatic/intestinal Rat cytochrome P450 3A2 / Cyp3a2 expression in the rat dasatinib study. Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement. Model and exposure: Seven-day oral apigenin regimen with subsequent dasatinib exposure. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  3. Apigenin decreased measured hepatic/intestinal Rat P-glycoprotein / Abcb1 transporters expression in the rat dasatinib study.

    Apigenin → Rat P-glycoprotein / Abcb1 transporters Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Apigenin pretreatment in the drug experiment", "comparator": "Drug-only controls", "endpoint": "Apigenin decreased measured hepatic/intestinal Rat P-glycoprotein / Abcb1 transporters expression in the rat dasatinib study.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Seven-day oral apigenin regimen with subsequent dasatinib exposure.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin decreased measured hepatic/intestinal Rat P-glycoprotein / Abcb1 transporters expression in the rat dasatinib study.
    primary_references
    Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602
    source_locator
    Reviewed reference api-rat-pgp; Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 888–894

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Seven-day oral apigenin regimen with subsequent dasatinib exposure. · Recorded from source · Recorded from source

    ### api-rat-pgp Apigenin decreased measured hepatic/intestinal Rat P-glycoprotein / Abcb1 transporters expression in the rat dasatinib study. Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement. Model and exposure: Seven-day oral apigenin regimen with subsequent dasatinib exposure. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.